CERO Therapeutics (NASDAQ: CERO) set for share and warrant delisting

Rhea-AI Filing Summary

Cero Therapeutics Holdings, Inc. is having its common stock and warrants removed from listing and registration on the Nasdaq Stock Market LLC. Nasdaq certifies that it has complied with its own rules and the requirements of Section 12(b) and related SEC Rule 12d2-2 for striking the securities from listing, and the issuer is stated to have complied with the exchange’s rules and SEC requirements governing withdrawal of the securities.

Filing Explained

Nasdaq has filed to remove CERO’s common stock and warrants from its listing and registration; the filing does not state when removal becomes effective.

The July 13, 2026 Form 25 notifies that Nasdaq is removing CERO Therapeutics’ common stock and warrants from Nasdaq listing and exchange registration; the filing records the removal action but does not provide an effective date.

The stated change concerns the securities’ listing and registration status, so if it takes effect, those classes would no longer be listed or registered on Nasdaq.

The filing leaves the timing of effectiveness and any alternative trading venue unspecified, making those items the key follow-up points.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 07/13/2026 - 01:28 PM Accepted by SEC EDGAR 07/13/2026 - 01:28 PM Learn about SEC filing dates

UNITED STATES

OMB APPROVAL

OMB Number:			3235-0080
Expires:	March 31, 2018
Estimated average burden
hours per response:			1.7

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 25

NOTIFICATION OF REMOVAL FROM LISTING AND/OR REGISTRATION
UNDER SECTION 12(b) OF THE SECURITIES EXCHANGE ACT OF 1934.

Commission File Number

333-259491

Issuer:	CERO THERAPEUTICS HOLDINGS, INC.
Exchange:	Nasdaq Stock Market LLC

(Exact name of Issuer as specified in its charter, and name of Exchange where security is listed and/or registered)

Address:	2201 Broadway, Suite 705
	Oakland	CALIFORNIA	94612
Telephone number:					4,159,940,582

(Address, including zip code, and telephone number, including area code, of Issuer's principal executive offices)

Common Stock, Warrants

(Description of class of securities)

Please place an X in the box to designate the rule provision relied upon to strike the class of securities from listing and registration:

17 CFR 240.12d2-2(a)(1)

17 CFR 240.12d2-2(a)(2)

17 CFR 240.12d2-2(a)(3)

17 CFR 240.12d2-2(a)(4)

Pursuant to 17 CFR 240.12d2-2(b), the Exchange has complied with its rules to strike the class of securities from listing and/or withdraw registration on the Exchange. ¹

Pursuant to 17 CFR 240.12d2-2(c), the Issuer has complied with its rules of the Exchange and the requirements of 17 CFR 240.12d-2(c) governing the voluntary withdrawal of the class of securities from listing and registration on the Exchange.

Pursuant to the requirements fo the Securities Exchange Act of 1934, Nasdaq Stock Market LLC certifies that it has reasonable grounds to believe that it meets all of the requirements for filing the Form 25 and has caused this notification to be signed on its behalf by the undersigned duly authorized person.

2026-07-13	By	Aravind Menon		Hearings Advisor
Date		Name		Title

¹ Form 25 and attached Notice will be considered compliance with the provisions of 17 CFR 240.19d-1 as applicable. See General Instructions.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.